UnitedHealth Group reports second quarter results on 16 July before the US market opens. The healthcare giant’s numbers will test the consensus narrative that drove UNH shares up 24% year to date: that the company can return to steady double-digit earnings growth after the tumultuous twelve months that sent the stock price down 30% since April last year.
Analysts covering UNH expect earnings per share of $4.85 on revenue of $110.82 billion for the three months ending 30 June. The EPS figure represents 19% growth compared to $4.08 in the same quarter last year, albeit a slight decline on revenue of $111.62 billion Y/Y.
The headline EPS beat-or-miss will matter, but the more important signals will come from Medicare Advantage performance, margin trajectory, and management commentary on the recovery path.
UnitedHealth’s Medicare Advantage business received a substantial boost this year through the federal quality bonus program. The company has roughly 24 million MA members enrolled in plans eligible for bonus payments in 2026, part of a broader $13.4 billion in federal funds flowing to MA insurers based on Star Ratings performance.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
That bonus structure rewards plans rated four stars and above with additional payments, and UnitedHealth holds the largest share of bonus-eligible membership across the industry.
The MA Star Ratings impact should show up in revenue per member and potentially in margin performance during the quarter. Investors will be watching whether the company can translate that bonus eligibility into visible financial results and whether management signals confidence that the rating structure remains stable heading into 2027.
The other major focus will be operating efficiency. The forward valuation story that helped propel shares higher since March rests on the thesis that UnitedHealth can grow earnings at roughly 16.5% annually while revenue expands at only 4.3% per year. That gap implies meaningful margin expansion or cost discipline over the next several years. Any guidance reset, revised outlook commentary, or unexpected pressure on medical loss ratios could test that thesis quickly.
The Setup at UNH
UnitedHealth shares collapsed between April 2025 and March of this year, falling back from $600 per share to $260 on the year.
Since that March low, the stock has staged a powerful recovery. UnitedHealth shares have now added 61% in four months and have reclaimed most of the ground lost during the crisis period.
The rebound has been driven partly by stabilisation in the regulatory environment, partly by better-than-feared claims trends, and partly by a broader market rotation back into large-cap healthcare names.
Markets are pointing to a move of ~6% in UNH following the print.
